The roles of self-efficacy and pretest counseling in type 2 herpes simplex virus screening in asymptomatic adults

被引:0
作者
Freeman, Matthew [1 ]
Zychowicz, Michael [2 ]
Feldman, Gary [3 ]
Gordon, Shelley [4 ]
机构
[1] Pacific Lutheran Univ, Ctr Hlth, Tacoma, WA 98447 USA
[2] Duke Univ, Sch Nursing, Durham, NC USA
[3] Feldman Med Grp, San Francisco, CA USA
[4] Calif Pacific Med Ctr, San Francisco, CA USA
来源
JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS | 2012年 / 24卷 / 05期
关键词
Herpes simplex; public health; routine; Sexually transmitted infections (STIs); screening; self-efficacy; sexual health; GENITAL HERPES; PREVENTION; ACYCLOVIR; TESTS;
D O I
10.1111/j.1745-7599.2011.00695.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: To evaluate the role of counseling for patients undergoing screening for type 2 herpes simplex virus (HSV-2). Using pre- and post-screening questionnaires, we evaluated correlations between demographic factors, measures of self-efficacy and follow-through with the screening test, and willingness to take antiviral medication and share results with sexual partners. Data sources: Subjects (N= 115) were recruited as part of usual care at a private, urban family practice. A total of 111 subjects completed pre-screening questionnaires, and 38 completed post-screening questionnaires. Conclusions: The overwhelming majority of participants were (a) willing to undergo screening; (b) take suppressive antiviral medication if necessary; (c) share their results with sexual partners; and (d) consider safer sexual practices as a consequence of screening. Older patients were less willing to consider daily antiviral medication. Men who have sex with men (MSM) had lower perceived susceptibility to HSV-2 but were more likely to undergo and report screening. Implications for practice: Future research should include predictive models for determining the most appropriate patients to screen for HSV-2 and best practices for those who test positive. Shared decision making between patients and advanced practice nurses regarding the risks and benefits of screening for HSV-2 should be a component visits that include sexually transmitted disease screening. Particular attention should be paid to those at higher risk for contracting the virus, including patients with HIV and MSM.
引用
收藏
页码:313 / 323
页数:11
相关论文
共 27 条
  • [1] [Anonymous], 2009, SEX TRANSM DIS SURV
  • [2] [Anonymous], CDC AN NAT HERP PREV
  • [3] GENITAL HERPES - DOES KNOWLEDGE LEAD TO ACTION
    ARAL, SO
    CATES, W
    JENKINS, WC
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1985, 75 (01) : 69 - 71
  • [4] Bandura A., 1997, SELF EFFICACY EXERCI
  • [5] Herpes simplex virus type 2 and HIV infection among US military personnel: implications for health prevention programmes
    Bautista, C. T.
    Singer, D. E.
    O'Connell, R. J.
    Crum-Cianflone, N.
    Agan, B. K.
    Malia, J. A.
    Sanchez, J. L.
    Peel, S. A.
    Michael, N. L.
    Scott, P. T.
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2009, 20 (09) : 634 - 637
  • [6] Beauman JG, 2005, AM FAM PHYSICIAN, V72, P1527
  • [7] California Department of Health, 2010, CAL SEX TRANSM DIS S
  • [8] Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2
    Celum, C.
    Wald, A.
    Lingappa, J. R.
    Magaret, A. S.
    Wang, R. S.
    Mugo, N.
    Mujugira, A.
    Baeten, J. M.
    Mullins, J. I.
    Hughes, J. P.
    Bukusi, E. A.
    Cohen, C. R.
    Katabira, E.
    Ronald, A.
    Kiarie, J.
    Farquhar, C.
    Stewart, G. J.
    Makhema, J.
    Essex, M.
    Were, E.
    Fife, K. H.
    de Bruyn, G.
    Gray, G. E.
    McIntyre, J. A.
    Manongi, R.
    Kapiga, S.
    Coetzee, D.
    Allen, S.
    Inambao, M.
    Kayitenkore, K.
    Karita, E.
    Kanweka, W.
    Delany, S.
    Rees, H.
    Vwalika, B.
    Stevens, W.
    Campbell, M. S.
    Thomas, K. K.
    Coombs, R. W.
    Morrow, R.
    Whittington, W. L. H.
    McElrath, M. J.
    Barnes, L.
    Ridzon, R.
    Corey, L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) : 427 - 439
  • [9] Celum C., 2002, INT C ANT AG CHEM SA
  • [10] Centers for Disease Control and Prevention, 1998, REP GEN HERP PREV CO